The Dijon biotech, specialist in drugs associated with emergency situations, announces that it has entered into a licensing agreement for the United States (United States and Canada) with Eton Pharmaceuticals. This laboratory, specializing in endocrinology, will market the Zeneo Hydrocortisone auto-injector developed by Crossject as an emergency treatment in adrenal crisis.
Without a needle, this product will be in the form of a first aid kit for patients and their families. Eton will be in charge of all regulatory and commercial activities, including MA applications.
In return for this agreement, Crossject will receive five million dollars (€ 4.2 million) before commercialization and will then receive a sale price for each product supplied to Eton as well as royalties of 10% on net sales, together with payments. up to $ 6 million conditional on the achievement of commercial milestones.
–
